Exploration of the antiplatelet activity profile of betulinic acid on human platelets

Journal of Agricultural and Food Chemistry

Volumn 60, Issue 28, 2012, Pages 6977-6983

  Tzakos, Andreas G ^a   Kontogianni, Vassiliki G ^a   Tsoumani, Maria ^a   Kyriakou, Eleni ^a   Hwa, John ^b   Rodrigues, Francisco A ^c   Tselepis, Alexandros D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ADP; antithrombotics; betulinic acid; platelet aggregation

Indexed keywords

ACTIVATED PLATELETS; ADENOSINE DIPHOSPHATE; ANTI-INFLAMMATORY ACTIVITY; ANTI-PLATELET ACTIVITIES; ANTIRETROVIRALS; ANTITHROMBOTIC; ANTITHROMBOTICS; ARACHIDONIC ACIDS; BETULINIC ACID; BIOLOGICAL ACTIONS; CARBOXYLATE GROUPS; FLOW-CYTOMETRIC ANALYSIS; IN-VITRO; P-SELECTIN; PHARMACOPHORES; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGONISTS; THROMBIN RECEPTORS; TRITERPENES;

ADMINISTRATIVE DATA PROCESSING; CARBOXYLATION; CHEMICAL ACTIVATION; CHEMICAL PROPERTIES; PHARMACODYNAMICS; PRINCIPAL COMPONENT ANALYSIS;

PLATELETS;

ANTITHROMBOCYTIC AGENT; BETULIC ACID; FIBRINOLYTIC AGENT; PADGEM PROTEIN; PROSTACYCLIN RECEPTOR; TRITERPENE;

ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; METABOLISM; THROMBOCYTE;

BLOOD PLATELETS; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; P-SELECTIN; PLATELET AGGREGATION INHIBITORS; RECEPTORS, EPOPROSTENOL; TRITERPENES;

EID: 84863965376     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf3006728     Document Type: Article

References (43)

1. Fareed, J.; Hoppensteadt, D. A.; Fareed, D.; Demir, M.; Wahi, R.; Clarke, M.; Adiguzel, C.; Bick, R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010 Semin. Thromb. Hemostasis 2008, 34 (1) 58-73
2. Gawaz, M. Platelets in the onset of atherosclerosis Blood Cells Mol. Dis. 2006, 36 (2) 206-210
3. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002 J. Nat. Prod. 2003, 66 (7) 1022-1037
4. Ganesan, A. The impact of natural products upon modern drug discovery Curr. Opin. Chem. Biol. 2008, 12 (3) 306-317
5. Janga, S. C.; Tzakos, A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery Mol. Biosyst. 2009, 5 (12) 1536-1548
6. Kyriakou, E.; Primikyri, A.; Charisiadis, P.; Katsoura, M.; Gerothanassis, I. P.; Stamatis, H.; Tzakos, A. G. Unexpected enzyme-catalyzed regioselective acylation of flavonoid aglycones and rapid product screening Org. Biomol. Chem. 2012, 10 (9) 1739-1742
7. Vasilopoulou, C. G.; Kontogianni, V. G.; Linardaki, Z. I.; Iatrou, G.; Lamari, F. N.; Nerantzaki, A. A.; Gerothanassis, I. P.; Tzakos, A. G.; Margarity, M. Phytochemical composition of "mountain tea" from Sideritis clandestina subsp. clandestina and evaluation of its behavioral and oxidant/antioxidant effects on adult mice. Eur. J. Nutr. 2011, DOI: 10.1007/s00394-011-0292-2.
8. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years J. Nat. Prod. 2007, 70 (3) 461-477
9. Chen, Y.; Deuster, P. Comparison of quercetin and dihydroquercetin: antioxidant-independent actions on erythrocyte and platelet membrane Chem.-Biol. Interact. 2009, 182 (1) 7-12
10. Jin, Y. R.; Han, X. H.; Zhang, Y. H.; Lee, J. J.; Lim, Y.; Chung, J. H.; Yun, Y. P. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-γ2 phosphorylation and cyclooxygenase-1 activity Atherosclerosis 2007, 194 (1) 144-152
11. Poeckel, D.; Tausch, L.; Altmann, A.; Feisst, C.; Klinkhardt, U.; Graff, J.; Harder, S.; Werz, O. Induction of central signalling pathways and select functional effects in human platelets by β-boswellic acid Br. J. Pharmacol. 2005, 146 (4) 514-524
12. Jager, S.; Trojan, H.; Kopp, T.; Laszczyk, M. N.; Scheffler, A. Pentacyclic triterpene distribution in various plants - rich sources for a new group of multi-potent plant extracts Molecules 2009, 14 (6) 2016-2031
13. Pisha, E.; Chai, H.; Lee, I. S.; Chagwedera, T. E.; Farnsworth, N. R.; Cordell, G. A.; Beecher, C. W.; Fong, H. H.; Kinghorn, A. D.; Brown, D. M. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis Nat. Med. 1995, 1 (10) 1046-1051
14. Eichenmuller, M.; Hemmerlein, B.; von Schweinitz, D.; Kappler, R. Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma Br. J. Cancer 2010, 103 (1) 43-51
15. Liby, K. T.; Yore, M. M.; Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer Nat. Rev. Cancer 2007, 7 (5) 357-369
16. de Sa, M. S.; Costa, J. F.; Krettli, A. U.; Zalis, M. G.; Maia, G. L.; Sette, I. M.; Camara Cde, A.; Filho, J. M.; Giulietti-Harley, A. M.; Ribeiro Dos Santos, R.; Soares, M. B. Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei -infected mice Parasitol. Res. 2009, 105 (1) 275-279
17. Chowdhury, A. R.; Mandal, S.; Mittra, B.; Sharma, S.; Mukhopadhyay, S.; Majumder, H. K. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives Med. Sci. Monit. 2002, 8 (7) BR254-BR265
18. Chintharlapalli, S.; Papineni, S.; Ramaiah, S. K.; Safe, S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors Cancer Res. 2007, 67 (6) 2816-2823
19. Fulda, S. Betulinic acid: a natural product with anticancer activity Mol. Nutr. Food Res. 2009, 53 (1) 140-146
20. Takada, Y.; Aggarwal, B. B. Betulinic acid suppresses carcinogen-induced NF-κB activation through inhibition of I κB α kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9 J. Immunol. 2003, 171 (6) 3278-3286
21. Vijayan, V.; Antony, H.; Varma, R. L. Betulinic acid inhibits endotoxin stimulated phosphorylation cascade and pro-inflammatory prostaglandin E(2) production in human peripheral blood mononuclear cells Br. J. Pharmacol. 2011, 162, 1291-1303
22. Evers, M.; Poujade, C.; Soler, F.; Ribeill, Y.; James, C.; Lelievre, Y.; Gueguen, J. C.; Reisdorf, D.; Morize, I.; Pauwels, R.; De Clercq, E.; Henin, Y.; Bousseau, A.; Mayaux, J. F.; Le Pecq, J. B.; Dereu, N. Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action J. Med. Chem. 1996, 39 (5) 1056-1068
23. Santos, R. C.; Matos Beja, A.; Salvador, J. A. R.; Paix̃o, J. A. 3β-Hydroxylup-20(29)-en-28-yl 1H-imidazole-1-carboxylate Acta Crystallogr. 2010, E66, o1878-o1879
24. http://www.chemaxon.com/.
25. Theodoridis, S.; Koutroumbas, K. Pattern Recognition; Academic Press: San Diego, CA, 2008.
26. Mitsios, J. V.; Tambaki, A. P.; Abatzis, M.; Biris, N.; Sakarellos-Daitsiotis, M.; Sakarellos, C.; Soteriadou, K.; Goudevenos, J.; Elisaf, M.; Tsoukatos, D.; Tsikaris, V.; Tselepis, A. D. Effect of synthetic peptides corresponding to residues 313-332 of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3 Eur. J. Biochem. 2004, 271 (4) 855-862
27. Olschewski, H.; Simonneau, G.; Galie, N.; Higenbottam, T.; Naeije, R.; Rubin, L. J.; Nikkho, S.; Speich, R.; Hoeper, M. M.; Behr, J.; Winkler, J.; Sitbon, O.; Popov, W.; Ghofrani, H. A.; Manes, A.; Kiely, D. G.; Ewert, R.; Meyer, A.; Corris, P. A.; Delcroix, M.; Gomez-Sanchez, M.; Siedentop, H.; Seeger, W. Inhaled iloprost for severe pulmonary hypertension N. Engl. J. Med. 2002, 347 (5) 322-329
28. Mitsios, J. V.; Stamos, G.; Rodis, F. I.; Tsironis, L. D.; Stanica, M. R.; Sakarellos, C.; Tsoukatos, D.; Tsikaris, V.; Tselepis, A. D. Investigation of the role of adjacent amino acids to the 313-320 sequence of the αIIb subunit on platelet activation and fibrinogen binding to αIIbβ3 Platelets 2006, 17 (5) 277-282
29. Dimitriou, A. A.; Stathopoulos, P.; Mitsios, J. V.; Sakarellos- Daitsiotis, M.; Goudevenos, J.; Tsikaris, V.; Tselepis, A. D. Inhibition of platelet activation by peptide analogs of the β(3)-intracellular domain of platelet integrin α(IIb)β(3) conjugated to the cell-penetrating peptide Tat(48-60) Platelets 2009, 20 (8) 539-547
30. Biris, N.; Abatzis, M.; Mitsios, J. V.; Sakarellos-Daitsiotis, M.; Sakarellos, C.; Tsoukatos, D.; Tselepis, A. D.; Michalis, L.; Sideris, D.; Konidou, G.; Soteriadou, K.; Tsikaris, V. Mapping the binding domains of the α(IIb) subunit. A study performed on the activated form of the platelet integrin α(IIb)β(3) Eur. J. Biochem. 2003, 270 (18) 3760-3767
31. von Hundelshausen, P.; Weber, C. Platelets as immune cells: bridging inflammation and cardiovascular disease Circ. Res. 2007, 100 (1) 27-40
32. Namba, T.; Oida, H.; Sugimoto, Y.; Kakizuka, A.; Negishi, M.; Ichikawa, A.; Narumiya, S. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla J. Biol. Chem. 1994, 269 (13) 9986-9992
33. Stoll, F.; Liesener, S.; Hohlfeld, T.; Schror, K.; Fuchs, P. L.; Holtje, H. D. Pharmacophore definition and three-dimensional quantitative structure-activity relationship study on structurally diverse prostacyclin receptor agonists Mol. Pharmacol. 2002, 62 (5) 1103-1111
34. Stitham, J.; Stojanovic, A.; Merenick, B. L.; O'Hara, K. A.; Hwa, J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling J. Biol. Chem. 2003, 278 (6) 4250-4257
35. Sturzebecher, S.; Witt, W. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation Prostaglandins 1988, 36 (6) 751-760
36. Iyu, D.; Glenn, J. R.; White, A. E.; Johnson, A. J.; Fox, S. C.; Heptinstall, S. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function Platelets 2010, 21 (5) 329-342
37. Iyu, D.; Glenn, J. R.; White, A. E.; Fox, S. C.; Dovlatova, N.; Heptinstall, S. P2Y(1)(2) and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP Platelets 2011, 22 (7) 504-515
38. Philipose, S.; Konya, V.; Sreckovic, I.; Marsche, G.; Lippe, I. T.; Peskar, B. A.; Heinemann, A.; Schuligoi, R. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation Arterioscler. Thromb. Vasc. Biol. 2010, 30 (12) 2416-2423
39. Lindemann, S.; Klingel, B.; Fisch, A.; Meyer, J.; Darius, H. Increased platelet sensitivity toward platelet inhibitors during physical exercise in patients with coronary artery disease Thromb. Res. 1999, 93 (2) 51-59
40. Sakamaki, F.; Kyotani, S.; Nagaya, N.; Sato, N.; Oya, H.; Satoh, T.; Nakanishi, N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy Circulation 2000, 102 (22) 2720-2725
41. Tennis, M. A.; Van Scoyk, M.; Heasley, L. E.; Vandervest, K.; Weiser-Evans, M.; Freeman, S.; Keith, R. L.; Simpson, P.; Nemenoff, R. A.; Winn, R. A. Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1 Neoplasia 2010, 12 (3) 244-253
42. Nemenoff, R.; Meyer, A. M.; Hudish, T. M.; Mozer, A. B.; Snee, A.; Narumiya, S.; Stearman, R. S.; Winn, R. A.; Weiser-Evans, M.; Geraci, M. W.; Keith, R. L. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ Cancer Prev. Res. (Phila.) 2008, 1 (5) 349-356
43. Keith, R. L.; Miller, Y. E.; Hoshikawa, Y.; Moore, M. D.; Gesell, T. L.; Gao, B.; Malkinson, A. M.; Golpon, H. A.; Nemenoff, R. A.; Geraci, M. W. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer Cancer Res. 2002, 62 (3) 734-740